# Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)

> **NCT00348153** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Heidelberg University** · enrollment: 40 (estimated)

## Conditions studied

- Uveitis

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT00348153
- **Lead sponsor:** Heidelberg University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-08
- **Primary completion:** 2012-09
- **Final completion:** 2013-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00348153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00348153, "Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00348153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*